Non-Hodgkin Lymphoma | Specialty

KTE-C19 Leads to High Response Rates in Refractory NHL

December 7th 2016

Almost 80% of patients with treatment-refractory non-Hodgkin lymphoma had objective responses following treatment with KTE-C19, a chimeric antigen receptor T-cell therapy targeting CD19.

Acalabrutinib Safe, Effective in Ibrutinib-Intolerant CLL/SLL

December 6th 2016

The investigational Bruton tyrosine kinase inhibitor acalabrutinib was shown to be well-tolerated in patients with chronic lymphocytic leukemia and small lymphocytic leukemia who display intolerance to ibrutinib (Imbruvica).

Frontline Obinutuzumab Significantly Improves PFS in Follicular Lymphoma

December 5th 2016

Combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 34% versus rituximab plus chemotherapy in patients with follicular lymphoma, according to findings from the phase III GALLIUM study.

Acalabrutinib Monotherapy Effective for Richter Transformation

December 4th 2016

The next-generation BTK inhibitor acalabrutinib produced an objective response rate of 38.1% as a monotherapy for patents with Richter transformation.

Expert Emphasizes Need to Enhance Treatment Strategies for Indolent Lymphomas

November 22nd 2016

Investigators are exploring therapy options for patients with indolent lymphomas—including follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma—as rituximab regimens are proving to not be a long-term option for many patients.

RT Plus Chemo Significantly Improves PFS in Follicular Lymphoma

September 28th 2016

Chemoradiation for early-stage, low-grade follicular lymphoma led to significant improvement in progression-free survival compared with involved-field radiotherapy alone.

KTE-C19 Induces Complete Remissions in Phase II Lymphoma Study

September 27th 2016

Treatment with KTE-C19 demonstrated an objective response rate of 79% and a complete remission rate of 52% for patients with aggressive, chemorefractory non-Hodgkin's lymphoma.

FDA Approval Sought for Ibrutinib in Marginal Zone Lymphoma

September 27th 2016

A supplemental new drug application has been submitted to the FDA for the use of ibrutinib as a treatment for patients with marginal zone lymphoma.

Individualizing Therapy for Patients With Waldenstrom's Macroglobulinemia

September 16th 2016

Improved understanding of Waldenström's macroglobulinemia and expanded treatment options have made individualized treatment based on clinical indications a feasible strategy

CAR T-Cell Therapy Continues to Show Promise in Non-Hodgkin Lymphoma

September 13th 2016

Chimeric antigen receptor T-cells offer highly effective therapy for patients with minimal residual disease or bulky disease in both aggressive and indolent B-cell non-Hodgkin lymphomas.

The Future of Myeloma Research

July 27th 2016

Relapse Type and Monoclonal Antibody Choice in Multiple Myeloma

July 27th 2016

Sequencing Monoclonal Antibodies in Myeloma

July 27th 2016

Moving Beyond Medians

July 27th 2016

Novel Agents with Len-Dex in Multiple Myeloma

July 27th 2016

Goals of Therapy for Relapsed Myeloma

July 27th 2016

Treatment Goals Based on Relapse Type in Myeloma

July 27th 2016

All Myeloma Relapses Are Not the Same

July 27th 2016

Efficacy and Safety of Monoclonal Antibodies for Multiple Myeloma

July 27th 2016

Monoclonal Antibodies for Multiple Myeloma

July 27th 2016